GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.

The verdict follows investigations initiated by China's Ministry of Public Security in June 2013. GSKCI will pay a fine of £297 million (3 billion RMB) to the Chinese Government, which will be ...

Two FTSE 100 stocks in Harvey Jones' portfolio have suffered double-digit losses. He's standing by them for now, but he's ...

The pipeline will run for about 213 kilometres to a $7.4 billion polyethylene plant where construction started last September ...